These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Determination of a novel paclitaxel derivative (NPD-103) in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
    Author: Zhang SQ, Chen GH.
    Journal: Biomed Chromatogr; 2009 May; 23(5):510-5. PubMed ID: 19016232.
    Abstract:
    A sensitive and specific ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS-MS) method for quantification of a newly developed anticancer agent NPD-103 has been established. An aliquot of human plasma sample (200 microL) was spiked with (13)C-labeled paclitaxel (internal standard) and extracted with 1.3 mL of tert-butyl methyl ether. NPD-103 was quantitated on a C(18) column with methanol-0.1% formic acid (75:25, v/v) as mobile phase using UPLC-MS-MS operating in positive electrospray ionization mode with a total run time of 3.0 min. For NPD-103 at the concentrations of 1.0, 5.0 and 10.0 microg/mL in human plasma, the absolute extraction recoveries were 95.58, 102.43 and 97.77%, respectively. The linear quantification range of the method was 0.1-20.0 microg/mL in human plasma with linear correlation coefficients greater than 0.999. The intra- and inter-day accuracy for NPD-103 at 1.0, 5.0 and 10.0 microg/mL levels in human plasma fell into the ranges of 95.29-100.00% and 91.04-94.21%, and the intra- and inter-day precisions were in the ranges of 8.96-11.79% and 7.25-10.63%, respectively. This assay is applied to determination of half-life of NPD-103 in human plasma.
    [Abstract] [Full Text] [Related] [New Search]